INTRAOPERATIVE ADM INISTRATION of the proteinase inhibitor aprotinin leads to a reduction in blood 1055 in cardiac surgery. thus decreasing the necessity for transfusion ofbanked b lood.I~6 The beneficial effect of other drugs, including desmopressin acetate (DDAVP. Rorer Pharmaceuticals, Ft. Washington. PA),1 prostacyclin,8and dipyridamole,9 on blood loss in patienu undergoing cardiac surgery has already been proven in controlled clinical studies. Aprotinin is a naturally occurring enzyme inhibitor derived from bovine lungs. It acts on trypsin, plasmin, tiss ue-kallikrein, and to a lesser degree. on plasma-kamkrein. 10.11 Moreover, it is reported to have direct plateletpreserving properties in very high dosages. 1 2 Although aprotinin has been weil known for many years and has been widely used for many surgical indications,lo its blood saving properties have only become evident since it has been used in very high doses. 4 The rationale for these high dosages is to achieve aprotinin plasma concentrations during cardiopulmonary bypass (CPB) that are able to inhibit kallikrein activation.
Based on previous investigations/' we postulated that the clinical effecl of aprotinin is based mainly on the inhibitio n ofthe eontaet phase of coagulatio n. During CPB, this system is aetivated by contaet of blood with artificial surfaces of the extraeorporeal circuit. ls This aetivation cannot be completely inhibited by heparin. However, the postoperative bleeding tendency after cardiac surgery seems to be primarily due to impaired platelet funetion.l~
Intraoperative stimulation of coagulation with generation ofthrombin may lead to plate letactivation. It is therefore coneeivable that additional inhibition of the contact phase of coagulation by aprotinin might cause a diminution of this bleeding tendency during and after CPB. However, the mecha nism underlying the benefit from aprotinin has not yet been elucidated eompletely.
This prospe1:tive, d o uble-blind, placebo-comrolled study was undertaken for two reasons: I) to aseertain the blood-saving elfeet of high-dose aprotinin in a homogeneous group of patients undergoing cardiae surgery, and 2) to o btain furthe r information about the mode of ac tio n of aprotinin.
Methods
Forty patients schedu led for eleetive primary myoeardial revascularization gave info rmed consent to participate in this study, which had been approved by the loeal ethical eommiltee. The study group eomprised o nly male patients wilh preoperative normal left ventricular function (eje<:-lion fraction [EF] > 40%i left ventrieular end-diastolic pressure [LVEDPj < 20 mmHg) and apreoperative hemoglobin concentration > 13.5 gldl who were not receiving preoperative anticoagulant treatment. Antiplatelel therapy wasstopped at least 5 days before surgery. Criteria for exclusion from the slUdy were any surgical procedures other than revascularization, duration of operation greater than 360 min, and reexploration due to surgical bleeding, which was de fined as an evident bleeding source found during reexploration.
Patients were randomly assigned to one of two groups: the aprati nin group (group A) and the control group (group C). Aprotinin and the respective placebo were provided by the manufacture r (Bayer AG, Leverk\lsen, FRG) in identical packages, each containing 12 boules that eould only be identified by the mndom number. Each boule of aprolinin contained 5 X lOs kallikrein inaetivator units (KIU) (= 70 mg) aprotinin in 50 ml 0.9% saline solutio n, and the placebo boules eontained only saline. The following dosage regimen was appHed: after induction of anesthesia and before surgery, patients received a loading dose of 2 X 10(1 KIU aprotinin over a 15-min period followed by a continuous infusion of5 X 10 5 KIU per h administered by an infusion pump for the entire duration of surgery. An additional bolus of 2 X 10 6 KJU wasadded to the pump prime ofthe heart-lung maehine. Patients in group C received an equal volu me of saline.
The indic:ation for intra-and postoperative transfusion of ho mologous blood or blood products was defined as a hematocrit of less than SO%. T he hematocrit was measured every 4 h within the fint 24 h postoperatively and then every 8 h undl discharge from the lCU.
Anesthetie, operative, and bypass management were standardized. Anesthesia was induced by Runitrazepam (0.02 mg/kg) and additional fe ntanyl (10-20 pg/ kg). Pancuronium (0.1 mg/ kg) was used to faeilitate tracheal intubation. An arterial catheter via the radial artery and a pu lmonary artery catheter via the right internal jugular vein were inserted after induction. Anesthesia was maintained with additio nal fentanyl. Ir necessary, enRurane o r isoflurane was added during sternotomy.
Mueosa heparin (375 U/kg,Roche, Basel, Switlerland) was injected via a central venous catheter before aortic eannulation. Further heparin (125 U I kg) was adrni nistered if the activated dOlling time (ACT) deereased helow 400 s. T he ACT was eootrolled every half hour during heparinization. The extracorporeal circuit consisted ofa bubble oxygenator (HiRex D 700, Dideco, Mirandola, Italy) that was primed with a 1,400 ml erystalJoidsolution eontaining 5.000 units of additional heparin , a cardiotomy reservoir (Dideco 0742, Mirandola, ftaly), roller pumps, and polyvinyl tubing without an arterial filter. Cardiopulmonary bypass was performed with moderate hypotherrnia of 30° C and a Aow rate of 2.4 I· min-
Myocardial preservation wasaehieved by infusion of I ,000 ml cold cardioplegic solution (Bretschneider HTK, F. Köhler Chemie, Alsbach, FRG, eontaining 9 mM potassium and 180 mM histidine) ioto the aortk root after aortic cross-damping. After completion of CPB, residual heparin was neutralized with protamine chloride in a ratio of 1.5 mg per 125 U of the initia l heparin dose. A cell separator without a special heparin admin istration suction Hne (Haemonetics, Munich, FRC) was o nly used to eoncentrate and wash the remaining blood of the oxygenator after termination of the bypass. Mecha nical ventilatio n was maintained postoperatively umil peripheral rewarming and stable cireulatory conditio ns were aehieved and no major bleeding was noted. The reservoir ofthe heart-Iung maehine was used to colleet shed mediastinal blood fo r retransfusion dur ing the early postoperative phase. T he drainage blood was retransfused up to 6 h after surgery if at least 250 ml were collected and its volume replacement was necessary.
lntra-and postoperative crystalloid and colloid infusion were recorded until the patient's discharge from the intensive care unit (ICU). Blood transfusions needed until discharge from the hospital we re also reeol'ded. Intraoperati ve blood loss was assessed by weigh ing the gaUles a nd sponges and measuring the content of the suetion reservoir. The Auid used for rinsing was subtracted from this amount. The intraoperative bleeding tendency was assessed by the surgeon and the anesthesiologist after protamine administration using a score ranging from one (minimal) 10 foul' (exeessive). POSloperative blood loss via the chest LUbes was measured 6, 12, and 24 h postoperalively and at the removal of the ehest LUbeS.
The red blood cell mass of the patients was calcu lated preoperatively, on the first postoperative day, and on discharge from the ICU by multiplying hematoerit with the blood volume, 15 which was derived from standard curves using the sex, age, and weighl orthe patient.
Blood sampies were take n from the central venous catheter 01' the arterial port of the e xtracorporeal eircu it at the followi ng times: I) after inductio n of anesthesia before aprolinin infusion, 2) before heparin administration, 3) 5 min after the start of CP8, 4) 30 min after the start ofCPB, 5) at the end ofCPB, 6) after chest closure, 7) 2 h postoperative1y, 8) on the first postoperative day, and 9) 7 days postoperatively. After discarding the first 10 ml, blood was drawn into EDTA tubes for platelet count, leukocyte count, and hematocrit or into acid-citrate-dextrose (ACD) solution (4:1) for all other measurements. The ACD blood was immediately centrifuged at 3,000 g for 10 min at room temperalure, and the plasma was separated from the cellular components. All plasma sampies were frozen at -40 0 C in aliquots and thawed only before testing.
Tissue plasminogen activator (tPA) concentration, the split products of cross-linked fibrin (D-dimers; Boehringer Mannheim, FRG), total degradation products of fibrinogen and fibrin (FSP; Organon Teknika, Heidelberg, FRG), and the complex of thrombin with antithrombin 111 (TAT; Behring, Marburg, FRG)16 were determined by sandwich ELISA using polydonal and monodonal antibodies. Calibration was performed with standard material supplied by the manufacturers. Results are given in nanograms per milliliter. Aprotinin plasma concentrations were quantified by means of a competitive ELISA according to Mue1ler-Esterl et al. 17 Total plasma protein was quantified with the Biuret method (Boehringer Mannheim, FRG). Spontaneous fibrinolytic activation in the native sampies and in their (essentially inhibitor-free) euglobulin fraction was estimated on plasminogen containing human fibrin plates. 18 Any development ofa lysis zone, regardless ofits area, was considered as an indication of extrinsic plasminogen activator(s) in the sampIe.
To determine the ACT, 2 ml ofblood were collected into vacuum tubes containing 12 mg eelite. The Hemoehron 800 (International Technidine Corp., NJ) was used according to the instructions ofthe manufacturer. Single measurements of ACT were performed every half hour and at all intraoperative measurement times. If the ACT exceeded 1,200 s, the measurement was stopped. Prothrombin time, thrombin time, and activated partial thromboplastin time (aPTT) were measured by routinely applied clotting methods. Bleeding time was determined after induction of anesthesia, after neutralizing the heparin effect with protamine chloride, and 4 h postoperatively in the ICU. Since the ear lobe is the only part of the body within (he reach of the anesthesiologist during surgery, sampies were taken from this body part. The subaqual bleeding method that isa modified Duke method was applied. 19 Summary data of all variables are, if not otherwise stated, expressed as mean ± SD. Analysis of variance (ANOVA) was used ifappropriate. The Mann-Whitney U test was applied where data did not follow anormal distribution according to the results of Shapiro's test for normality. The chi-squared test was used for categorical data. P < 0.05 was considered statistically significant.
Results
Data of20 patients in group C and 19 patients in group A were evaluated. One patient (group A, patient 4) was excluded from analysis because of an additional intraoperative procedure (resection of a left ventricular aneurysm) that led to a prolongation of the operation. Reexploration due to surgical bleeding was not necessary.
As shown in table I, patients in the lwo groups were comparable in terms of age, weight, operation, :md CPB time. Thirteen patients in group C and II patients in group A also had additional internal mammary artery implantation.
Intraoperative blood loss per patient was 636 ± 322 ml in group C and 363 ± 159 ml in group A (P < 0.05).
The postoperative blood loss is given in figure I . The mean cumulated loss 6,12, and 24 h postoperatively per patient was 721 ± 471 ml, 894 ± 491 ml, and 1,169 ± 605 ml, respectively, in group C and 303 ± 209 ml, 399 ± 251 ml, and 584 ± 295 ml, respectively, in group A. The total postoperative blood loss per patient until removal ofthe chest tubes was 1,431 ± 760 ml in group C and 738 ± 411 ml in group A (P < 0.05). One patient (patient 37) in group C had a total blood loss of 3,550 ml. Since all hemostatic parameters were within the normal range, this blood loss was probably due to surgical bleeding; however, reexploration was not performed in this patient. Even after excluding this patient from analysis, the difference in blood loss between the groups was still significant (P < 0.05) at each stage. A total of 663 ± 171 ml per patient (group C) and 731 ± 283 ml per patient (group A) autologous packed cells gained with the cell separator from the oxygenator were retransfused (not significant [NS] ). Two patients in group C and one patient in group A received homologous blood intraoperatively. A mean of 431 ± 367 ml of drainage blood (maximum, 1670 ml [patient 37])and 147 ± 188 ml ofdrainage blood (maximum, 810 ml [patient 39]) was retransfused via the reservoir postoperatively in group C and A, respectively. The mean amount ofintra-and postoperatively transfused whole blood was 838 ± 963 ml per patient in group C and 163 ± 308 ml per patient in group A (P < 0.05).
A total of 2.3 ± 2.2 U per patient of homologous blood or blood products (i.e., blood, packed cells, or fresh-frozen plasma) were given in group C and 0.63 ± 0.96 U per patient in group A (P < 0.05). In group C, 46 U of homologous blood were transfused to 15 patients, representing a mean of 3.1 U per patient; whereas in group A, 12 U were given to seven patients, representing a mean T ABL"E I P:lltient Data "' ""C ., 
A (fig. 2). The correlation belween total blood requirement and duration of operation was also only significanl (P < 0.05) in group C.
The bleeding score as an assessment of intraopetative bleedi'ng tendency(ranging from minimal (4]) was 3.15 in group C and 2.3 in group A (P < 0_05). The hematocrit on the first postoperative day was 33.7 ± 4.1% in group e and 37.9 ± 2.9% in group A (P < 0.05). The preoperatively ealculated red blood cell mass was 2,428 ± 283 ml and 2,572 ± 300 ml in groups C and A, respectively (NS). At discharge from the ICU. it differed significantly: 1,846 ± 234 ml in group C and 2,027 ± 168 ml in group A (P < 0.05). This differenee remained signifieant until the seventh postoperative day when the red blood cell mass was 1,954 ± 312 ml in group e and 2,137 ± 214 ml in group A (P < 0.05). The elapsed time between end of ePB and ehest dosure was 55 ± 19 min in group e and 46 ± 11 min in group A (NS). After CPB, the preoperative platelet count dropped from 213 ± 58 X 109/ltoI29±58X 10 9 /1 in groupCand from 193 ± 44 X 10 9 / 1 to 115 ± 47 X 10 9 / 1 in group A (NS). The ACT, whieh was in a comparable range preoperatively in the two groups. was significantly increased 5 min before administration of heparin in group A (141 ± 13 s VS. 122 ± 25 5) and remained significantly higher until antagonizing the effect of heparin after CPB. The aPTT was also significantly increased before heparin in group A (34 ± 2.8 svs. 74 ± 7.3 s; P < 0.05)and remained significamly prolonged until 2 h after surgery (66 ± 23 s us. 45 ± 25 s). The preoperative bleeding time in groups C (180 ± 45 s) and A (178 ± 27 s) were within the normal range; however, 4 h postoperatively, it was 213 ± 46 s in group A and 290 ± 114 s in group C (P < 0.05).
There were no differenees in the total plasma protein eoneentrations between the groups throughout the study period. The coneentration of the TAT complex is given in figure 3 . The differences between the groups 30 min after start ofCPB and at the end ofCPB were significam (P< 0.05) with 48 ± 21 ng/ml and 82 ± 42 ng/ ml in group C compared to 24 ± 11 ng/ml and 42 ± 14 ng/ ml in group A. The concentration of the split products of the crosslinked fibrin (D-dimers) increased in both groups during surgery ( fig. 4) . The inerease was less in the aprotinin group, however, and was 532 ± 1,425 ng/ml and 497 ± 1,398 ng/ml 30 min after onset ofCPB and at the end of CPB, respectively, which is significantly less than the values of group C (2,155 ± 2,300 ng/ml and 3,131 ± 2,755 ng/ml). The FSP concentrations showed a similar course ( fig. 5 ). At the end ofCPB. the coneentration was 10,824 ± 7,261 ng/ml in group C and 2,510 ± 3,932 ng/ml in the group A (P < 0.05).
The fibrin plates revealed increased fibrinolytic aetivity ' during the entire course of ePB in the control group (table 2 ). In the native sampies, fibri nolytic activity was evident in 12 patients 5 min after onsel of ePB and in 1 S patients 30 min after onsel ofePB in the control grOUpj however. this could not be demonstrated 5 min after the start of CPB and in eight patients 30 min after the slart ofCPB in the aprotinin group (P < 0.05). At the end of CPB, however, fibrinolytic activity could be seen in 15 patien15 in group e and in 14 patien15 in group A. The quantitative measuremenl of the lysis spots is given in table 2. At the end ofthe operation, no differences cou ld be determined. In contrasI, lhe tPA concentration was not significantly different during the course of surgery. It increased from 6 ± 3.7 ng/ ml preoperatively to 18 ± 10 ng/ ml at the end of CPB in group e and from 6 ± 2.3 ng/ ml to 16 ± 9 ng/ ml in group A. None of the laboratory results showed any significa nt difference arter the first postoperative day.
The aprotinin plasma concentration ( fig. 6 ) dem onstrated an increase from 152 ± 6 1 KIU / ml before heparin tO 335 ± 106 KlU/ ml5 min after onset ofePB . Thereafter. a continuous decrease was found until the end of CPB (191 ± 62 KIU/ ml). Two hours after surgery, the aprotinin concentration was 74 ± 3 1 KIU /ml.
The postoperative course of all patien15 was uneventful. No clinically relevant side effects could be attributed to aprotinin treatment.
Discussion
This study clearly demonstrates the influence of highdose aprotinin treatment given during the entire course of open heart surgery on intra-and postoperative blood loss. Comparing homogeneous patient groups, a highly significant reduction of intra-and postoperative blood loss was found in the aprotinin-treated group. This reduction led to a concomitant saving of homologous blood. Post- operative blood loss was reduced by 48%. whereas the banked blood requirement was diminished by nearly 80%. The reduced bleeding tendency was clinically evident as shown by the different bleeding scores given for the two groups by the surgeon and the anesthesiologist. This study corroborates the results of ou r previous investigation~ and those of others 2 • 4 that also show a numerical discrepancy between the degrees of postoperative bleeding reduction and transfusion requirement. This discrepaney may be explained by the fact that, due to intraoperativeJy deereased blood loss, the red blood eell mass or hematocrit remains higher as an effect of aprotinin treatment. thus lessening the need for homologous blood transfusion. Furthennore, the hemoglobin COOleOl and. consequeOlly. hemoglobin loss via ehest tubes are diminished in this patient group, where the drainage Auid consists mainly of infiammatoryexudation. 4 The differences between the two groups with regard to bleeding and banked blood requirement agree with the reSullS of other studies using the same or a similar aprotinin dosage regimen. All studies using aprotinin during coronary artery bypass grafting showed nearly idemical reductions in blood lo~: Bidstrup er 01.,16%2;
Van Oeveren tl 01., 47%20; and Fraedrich t/ 01 .• 46%'. However, the reduction in a group of patients with miscel1aneous types of operations was 29%,& The blood·saving effcct in these studies varied between 43'and 88%. 4 This blood·saving elftet is due not only to reduction of postoperative blood 1055 but also to diminished intraoperative bleeding tendency as shown in the current study.
The strong correlation between the duration of CPB and intraoperative blood loss, which was evident in the patients of the control group, (Quld not be demonstrated in the aprotinin-treated patients.
Nevertheless, the mode of action of aprotinin is not yet completely dear. Capillary bleeding and oozing in cardiac surgery are believed to be due (0 impaired platelet function. The most importamconsequence ofCPB isthe loss of platelet aggregability. 1' ,21 Platelet activation occurs as a direct result of the contact of blood with a symhetic surface during CPB. The inHuence ofaprotinin on platelet adhesive receptorscould be demonstrated in one study.20
ConsequeOlly, a direct platelet-preserving property of aprotinin has been poslUlated. 20 The effect of aprotinin on platelets-of primary or secondary nature-is unquestionable. In accordance with others,2 we observed a shorter postoperative bleeding time with aprolinin trcatmeOl as a result of better preserved platelet function; however, the platelet count did not differ between bOLh groups during the whole operation.
The surface-mediated activation ofthe contact system of coagulation involves the imeraction of factor XII (Hageman factor) and kallikrein (besides high molecular weight kininogen and factor XI).t2 Aprotinin may inhibit kallikrein. Without the amplifying eifect of kallikrein on the conversion of factor XII to Xlla, the contact phase activation i5 inhibited or takes place only slowly. Major consequences of the surface-mediated activation are the stimulation ofboth the intrinsic pathway of coagulation U with the effecl ofthrombin formation and the propagation of the fibrinol)'tic pathway leading LO pla5minogen activalion. While activation of the contact system has no major direct etrect on platelet activation,24 thrombin is a powerful platelet activator, Therefore, it is conceivable that the effect of aprotinin on platelets is seconda ry tO the inhibition ofthe contact system of coagulation .
Indeed, the significant reduction of the D-dimers and the thrombin-anti thrombin 111 complex concentration found in the current study indicates less thrombin generation, and the results achieved with the fibrin plates demonstrate less fibrinolytic activity during aprotinin application. The inhibition of the contact phase of coagulation due to aprotinin is responsible for this reduced thrombin formation. Both diminished thrombin generalion and fibrinolysiscaused less formation ofthe fragments of fibrinogen and fibrin.
Aprotinin is a powerful plasmin inhibitor.2~ While we observed differences in the results ofthe fibrin plates between the groups, we could not detC1:t any significant difference in the course of tPA concentration, The immunoassay, however. ma)' not differentiate free and complexed tPA. Plasma kallikrein inhibition not only leads LO reduced contact activation of coagulation but can also cause reduced fibrinolytic activalion,24,26 The current findings indicate that endothelial activation of fibrinolysis is not inhibited by aprotinin, whereas the activation via plasma kallikrein is auenuated. The course of the ACT, which is an indicator of contact activation,27 and the aPTT elevation with aprotinin treatment refer to the inhibition of the contact phase of coagulation. These results strongly suggest that the inhibition of the contact phase of coagulation is the primary effect of aprotin in action and therefore responsible for the blood-saving cffect of this drug. This !inding i5 in contrast to the interpretation given by yan Oeveren tt 01,2(1 who focused on the direct platelet protective effect of aprotinin on the speci fic platclel receptors, Inhibition of fibrinolysis and the better preserved ptatelet function are of secondary nature.
The rationale for choosing the given aprotinin dose regimen was to get a constant aprotinin plasma concentration of more than 200 KIU / ml. which is supposed to be the threshold of plasma kallikrein inhibition, 28 The time course of plasma aprotinin concentration revealed that the aprolinin dose used did nOI maintain a stable concentration throughout CPB. However, the inhibitor concentration exceeded 200 KIU/ ml afteronset ofCPB.
It might be possible that a higher aprotinin concentration at the start of CPB is desirable because surface activation takes place mainly during the initial phase of CPB. The course of the fibrin-fibrinogen split products and the results of the fibrin plates demonstraled that aprotinin, at least in the dosage given, was not able to completely suppress the ongoing hem05tatic activation, All parameters 5howed an increase toward the end of CPB. Further investigation is needed to ascertain whether this tendency can be prevented with another (i.t, , highcr) dose regi men ofaprotinin du ring CPB, The interindividual differences in the aprotinin levels do seem to warrant the application of a body weight-oriented dosage ofaprotinin instead of a fixed dose.
We conclude that high-dose aprotinin treatment has a highly beneficial effect on the hemostatic mechanism during and after CPB, leading tO a substantial reduction of intra-and postoperative bleeding tendency. The most likely mechanism of aprotinin action is the inhibition of kallikrein. The current results show that the dosage of aprotinin does not provide a constant aprotinin concentration during CPB. Further studies are required to delineate the precise mode of aprotinin action and to determine the most effective aprotinin dosage.
